Ipilimumab

證據等級: L5

預測適應症: 2 個

Ipilimumab: From Melanoma to Choroideremia

One-Sentence Summary

Ipilimumab is an anti-CTLA-4 immune checkpoint inhibitor historically used in melanoma immunotherapy. The TxGNN model predicts it may be effective for Choroideremia, but currently 0 clinical trials and 0 publications support this specific direction, and the mechanistic rationale is judged biologically implausible.

Quick Overview

Item	Content
Original Indication	Melanoma (official approved-indication text unavailable — see data gap DG001)
Predicted New Indication	Choroideremia
TxGNN Prediction Score	99.06%
Evidence Level	L5
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002). Based on known information, ipilimumab is a monoclonal antibody that blocks CTLA-4, releasing inhibition of T-cell activation to enhance the immune response against tumor antigens — a mechanism established through its use in melanoma.

Choroideremia, however, is a monogenic disease caused by CHM gene mutations leading to Rab escort protein 1 (REP1) deficiency, resulting in progressive choroidoretinal degeneration through a protein-trafficking defect. This pathophysiology has no known biological connection to CTLA-4-mediated immune checkpoint signaling.

Given the absence of any supporting clinical trial or literature evidence despite a high TxGNN score, this prediction is best interpreted as a knowledge-graph embedding artifact (a statistical co-occurrence pattern) rather than a mechanistically grounded repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Cytotoxicity

(Included because the original indication, melanoma, is an oncologic condition.)

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-CTLA-4 immune checkpoint inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN score (99.06%), there is no clinical trial or literature evidence supporting ipilimumab for choroideremia, and the proposed mechanistic link (CTLA-4 immune checkpoint blockade vs. a REP1 protein-trafficking defect) has no established biological basis. This candidate should not advance without independent mechanistic or preclinical justification.

To proceed, the following is needed:

Preclinical or mechanistic data establishing a plausible link between CTLA-4 pathway modulation and CHM/REP1-related choroidoretinal degeneration
TFDA label data (warnings/contraindications) to close data gap DG001
Confirmed mechanism of action (MOA) documentation to close data gap DG002

Note: This evidence pack also contains a second candidate for ipilimumab — non-cutaneous melanoma (TxGNN score 99.02%, Evidence Level L1, recommendation “Proceed with Guardrails”) — supported by a Phase 3 RCT (NCT02506153) and peer-reviewed literature (e.g., PMID 24999899 on uveal/mucosal melanoma). Given its substantially stronger evidence base, it may warrant a separate evaluation report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.